Connect Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Connect Biopharma Holdings
CNTB Stock  USD 2.65  0.05  1.92%   
Connect Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Connect Biopharma's valuation are provided below:
Gross Profit
762 K
Market Capitalization
145.3 M
Enterprise Value Revenue
115.4789
Revenue
762 K
Earnings Share
(0.89)
We have found one hundred twenty available fundamental signals for Connect Biopharma Holdings, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Connect Biopharma Holdings prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 28, 2026, Market Cap is expected to decline to about 71 M. The current year's Enterprise Value is expected to grow to about (43.9 M)

Connect Biopharma Total Revenue

31.43 Million

Check Connect Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Connect Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 27.8 K, Other Operating Expenses of 58 M or Tax Provision of 243.6 K, as well as many indicators such as Price To Sales Ratio of 2.34, Dividend Yield of 0.0 or PTB Ratio of 0.78. Connect financial statements analysis is a perfect complement when working with Connect Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Connect Stock
Check out the analysis of Connect Biopharma Correlation against competitors.

Connect Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets154.8 M116.5 M106.5 M
Slightly volatile
Short and Long Term Debt Total152.2 K160.2 K46.6 M
Slightly volatile
Other Current Liabilities9.2 M8.8 M2.6 M
Slightly volatile
Total Current Liabilities12.3 M9.7 M6.4 M
Slightly volatile
Property Plant And Equipment Net4.9 M4.9 M2.6 M
Slightly volatile
Accounts Payable373.6 K393.3 K2.6 M
Slightly volatile
Cash124.6 M90 M88.1 M
Slightly volatile
Non Current Assets Total7.9 M5 M4.3 M
Slightly volatile
Non Currrent Assets Other28.2 K29.7 K719.7 K
Pretty Stable
Cash And Short Term Investments144.1 M107.8 M99.8 M
Slightly volatile
Net Receivables1.7 M1.2 M986.9 K
Slightly volatile
Short Term Investments17.2 M17.8 M8.7 M
Slightly volatile
Non Current Liabilities Total560.9 K590.4 K70.8 M
Slightly volatile
Other Current Assets2.8 M2 M2.9 M
Pretty Stable
Other Stockholder Equity530.3 M505.1 M153.9 M
Slightly volatile
Total Liabilities7.8 M8.2 M76.7 M
Slightly volatile
Total Current Assets147.1 M111.5 M102.3 M
Slightly volatile
Short Term Debt185.2 K354.2 K127.9 K
Slightly volatile
Common Stock7.8 K11.5 K5.6 K
Slightly volatile
Property Plant Equipment99.2 M94.5 M33.1 M
Slightly volatile
Common Stock Shares Outstanding60 M63.5 M56.1 M
Slightly volatile
Capital Lease Obligations152.2 K160.2 K851.7 K
Pretty Stable
Property Plant And Equipment Gross5.9 M6.2 M13.7 M
Slightly volatile
Capital Stock8.6 K9 K23.7 K
Very volatile
Non Current Liabilities Other540.4 K568.8 K500.3 M
Slightly volatile
Net Working Capital75.7 M79.6 M431.1 M
Very volatile
Intangible Assets45.3 K47.7 K443.8 K
Pretty Stable
Other Liabilities4 M4.5 M4.9 M
Slightly volatile
Current Deferred Revenue140.2 K147.6 K11 M
Slightly volatile

Connect Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses58 M55.8 M28.6 M
Slightly volatile
Interest Income3.7 M5.1 M2.3 M
Slightly volatile
Depreciation And Amortization667 K759 K358.6 K
Slightly volatile
Selling General Administrative12.4 M22.1 M6.7 M
Slightly volatile
Research Development54.3 M33.6 M30.8 M
Slightly volatile
Total Operating Expenses67.6 M55.8 M37.6 M
Slightly volatile
Reconciled Depreciation721 K759 K1.4 M
Pretty Stable
Cost Of Revenue714.3 K594 K962 K
Slightly volatile
Selling And Marketing Expenses10.8 M12.2 M13.3 M
Slightly volatile

Connect Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.2 M759 K866.4 K
Pretty Stable
Capital Expenditures819.4 K862.5 K4 M
Pretty Stable
End Period Cash Flow66.9 M70.4 M348.4 M
Pretty Stable
Change To Netincome889.9 M847.5 M322.4 M
Slightly volatile
Change To Liabilities68.3 M65.1 M23.7 M
Slightly volatile
Stock Based Compensation9.3 M6.1 M5.3 M
Slightly volatile
Begin Period Cash Flow90.3 M95.1 M132.9 M
Pretty Stable
Dividends Paid194.4 K218.7 K238.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.342.632.8748
Slightly volatile
Days Sales Outstanding11.7913.2614.4756
Slightly volatile
Average Payables4.7 M7.4 M4.9 M
Slightly volatile
Stock Based Compensation To Revenue0.210.230.2539
Slightly volatile
Capex To Depreciation1.241.312.5899
Pretty Stable
Payables Turnover0.0880.120.0934
Slightly volatile
Sales General And Administrative To Revenue0.590.660.7253
Slightly volatile
Research And Ddevelopement To Revenue0.91.011.1039
Slightly volatile
Capex To Revenue0.0230.02590.0283
Slightly volatile
Cash Per Share2.861.951.6666
Slightly volatile
Days Payables Outstanding3.9 K3.3 K4 K
Slightly volatile
Income Quality1.431.360.7028
Slightly volatile
Intangibles To Total Assets4.0E-45.0E-40.0014
Pretty Stable
Net Debt To EBITDA3.383.221.9871
Slightly volatile
Current Ratio24.0613.1844.3412
Slightly volatile
Receivables Turnover19.8222.2924.3327
Slightly volatile
Capex Per Share0.01480.01560.0201
Slightly volatile
Revenue Per Share0.380.420.4631
Slightly volatile
Interest Debt Per Share0.00370.00290.0033
Slightly volatile
Debt To Assets0.00190.0020.6713
Slightly volatile
Days Of Payables Outstanding3.9 K3.3 K4 K
Slightly volatile
Ebt Per Ebit0.750.791.4984
Pretty Stable
Long Term Debt To Capitalization1.021.161.2613
Slightly volatile
Quick Ratio23.8613.1844.2567
Slightly volatile
Net Income Per E B T0.80.910.974
Slightly volatile
Cash Ratio21.1610.6339.6581
Slightly volatile
Days Of Sales Outstanding11.7913.2614.4756
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.191.0429
Slightly volatile
Fixed Asset Turnover4.915.536.0355
Slightly volatile
Debt Ratio0.00190.0020.6713
Slightly volatile
Price Sales Ratio2.342.632.8748
Slightly volatile
Asset Turnover0.210.230.2527
Slightly volatile

Connect Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap71 M74.7 M689.6 M
Slightly volatile

Connect Fundamental Market Drivers

Forward Price Earnings0.7669
Cash And Short Term Investments93.7 M

Connect Upcoming Events

9th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Connect Biopharma Financial Statements

Connect Biopharma stakeholders use historical fundamental indicators, such as Connect Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Connect Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Connect Biopharma's assets and liabilities are reflected in the revenues and expenses on Connect Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Connect Biopharma Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue147.6 K140.2 K
Total Revenue29.9 M31.4 M
Cost Of Revenue594 K714.3 K
Stock Based Compensation To Revenue 0.23  0.21 
Sales General And Administrative To Revenue 0.66  0.59 
Research And Ddevelopement To Revenue 1.01  0.90 
Capex To Revenue 0.03  0.02 
Revenue Per Share 0.42  0.38 
Ebit Per Revenue(0.78)(0.82)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America
When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:
How To Invest In Connect
Details
Is Connect Stock a good investment?
Details
What is Connect Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Connect Biopharma Correlation against competitors.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.89)
Revenue Per Share
0.014
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.39)
Return On Equity
(0.67)
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY